Načítá se...
Use of vonoprazan for management of systemic sclerosis-related gastroesophageal reflux disease
Gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc) can significantly reduce a patient's quality of life. GERD in SSc is occasionally resistant to conventional anti-acid treatment. Vonoprazan is an H(+)/K(+)-ATPase blocker that is approved in Japan for treatment of GERD. The aim...
Uloženo v:
| Vydáno v: | Biomed Rep |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
D.A. Spandidos
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7780750/ https://ncbi.nlm.nih.gov/pubmed/33408859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/br.2020.1401 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|